Curapath is proud to announce the renewal of its Crédit Impôt Recherche (CIR)
accreditation up to 2027.
Granted by the French Ministry of Higher Education and Research, this accreditation
allows French companies collaborating with Curapath to continue benefiting from the
R&D tax credit on eligible research and development expenditures.
The Crédit Impôt Recherche program is one of France’s key initiatives to promote
scientific innovation, supporting partnerships that advance technological progress
across the pharmaceutical and biotechnology industries.
Through this renewal, Curapath reaffirms its long-standing commitment to fostering
innovation and facilitating collaborations that accelerate the development of advanced
drug delivery technologies.
As a European GMP-certified CDMO specialized in lipid and polymer-based delivery
systems, including LNPs, PNPs, and innovative excipients, Curapath provides
integrated support from research to clinical manufacturing.
Our CIR accreditation ensures that French partners can engage with us on eligible R&D
activities under favorable fiscal conditions, strengthening our shared capacity to bring
novel therapies closer to patients.
This continued recognition reflects Curapath’s dedication to scientific excellence,
transparency, and collaboration, values that drive our mission to empower innovators
in the fields of gene therapy, RNA delivery, and advanced pharmaceutical formulation.
